시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
암 바이오마커 시장 분석 및 예측(-2034년) : 유형, 제품, 서비스, 기술, 용도, 최종 사용자, 설치 유형, 기능, 단계
Cancer Biomarkers Market Analysis and Forecast to 2034: Type, Product, Services, Technology, Application, End User, Installation Type, Functionality, Stage
상품코드 : 1762091
리서치사 : Global Insight Services
발행일 : 2025년 07월
페이지 정보 : 영문 356 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,750 ￦ 6,905,000
Single User License help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능하며, 인쇄는 가능합니다.
US $ 5,750 ￦ 8,358,000
Site License help
PDF, Excel 보고서를 동일 기업(국가)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,750 ￦ 9,812,000
Enterprise License help
PDF, Excel 보고서를 동일 기업의 전 세계 모든분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

암 바이오마커 시장은 2024년 244억 달러에서 2034년에는 603억 달러로 확대되며 CAGR은 약 9.5%를 나타낼 것으로 예측됩니다. 표적 치료를 가능하게 함으로써 맞춤형 의료를 촉진합니다. 시장은 암 이환율 증가와 함께, 유전체학, 단백질체학, 바이오인포매틱스의 진보에 의해 확대하고 있습니다.

업계 개요

암 바이오마커 시장은 특히 동아시아에서 세계의 관세와 지정학적 긴장의 영향을 복잡하게 받고 있습니다. 중국은 수출 규제와 국산 혁신에 대한 주력을 원동력으로 의학 연구의 자급자족을 향한 전략적 축족을 가속시키고 있습니다. 하지만 미국과 중국의 긴장 속에서 지정학적 취약성에 직면하고 있습니다. 체인과 전략적 제휴를 조건으로 시장은 크게 성장할 것으로 예측됩니다.

시장 세분화
유형 게놈 바이오마커, 단백질 바이오마커, 대사 바이오마커, 후성유전 바이오마커
제품 분석 키트, 시약, 기기, 소프트웨어
서비스 샘플 준비, 바이오마커 검증, 바이오마커 테스트, 데이터 분석
기술 차세대 시퀀싱, 중합 효소 연쇄반응, 면역 분석, 질량 분석, 크로마토그래피
용도 진단, 제약 및 개발, 예후, 위험 평가
최종 사용자 병원, 연구소, 제약 회사, 생명 공학 회사, 학술 기관
설치 유형 온프레미스, 클라우드 기반
기능 감지, 모니터링, 프로파일링
단계 조기 발견, 예후, 치료 반응, 재발

시장 개요 :

암 바이오마커 시장은 맞춤형 의료의 진전과 암 이환율 증가를 주요 요인으로서 강력한 성장을 이루고 있습니다. 특정 암종을 검출하고 표적 요법을 이끄는 기술적 우위성에 의해 강화되고 있습니다. 이러한 바이오마커는 조기 발견과 맞춤형 치료 전략을 가능하게 함으로써 암 치료에 혁명을 일으킬 수 있습니다. 궤양의 동태를 실시간으로 파악할 수 있는 능력으로 시장에 큰 영향을 줄 것으로 예측됩니다.

충돌 개요 :

암 바이오마커 시장은 주로 진단 용도가 견인하고, 예후 예측이 근소한 차이로 계속되고 있습니다. 지출에 힘입어 시장을 선도하고 있습니다만, 아시아태평양은 헬스케어 투자 증가와 암 이환율의 상승에 의해 가속적인 성장을 이루고 있습니다. 한편, 아시아태평양은 의료 투자 증가와 암 이환율의 상승에 의해 성장이 가속하고 있습니다. 오마커 탐색 및 검증 혁신을 통해 포트폴리오를 지속적으로 강화하고 있습니다. 특히 미국과 유럽의 규제 프레임 워크는 바이오마커 검증 및 임상 사용에 대한 엄격한 지침을 제정하므로 시장 역학을 형성하는 데 매우 중요합니다. 신규 바이오마커의 동정과 활용에 길을 열고 있어 암 바이오마커 시장의 미래는 유망합니다. 규제상의 허들이나 개발 비용의 높이라고 하는 과제가 남아 있는 한편, 바이오마커 분석에 있어서의 인공지능의 통합이나 리퀴드 바이옵시로의 변화는 큰 성장 기회를 가져옵니다.

주요 동향과 촉진요인 :

암 바이오마커 시장은 정밀의료와 개별화 헬스케어의 진보에 의해 강력한 성장을 이루고 있습니다. 성장 촉진요인으로는 암 연구와 바이오마커 개발을 지원하는 정부의 대처나 자금 원조를 들 수 있습니다. 동반진단의 중요성은 시장 확대를 더욱 강화하고 있습니다. 개발에 주력하는 기업은 큰 시장 점유율을 획득할 수 있을 것으로 보입니다.

억제요인과 도전 :

암 바이오마커 시장에는 몇 가지 중요한 억제요인과 과제가 있습니다. 자동차 탐색을 더욱 복잡하게 하고, 연구기간의 장기화와 비용의 증대를 초래하고 있습니다. 라인이 없기 때문에 검사 결과에 편차가 생겨 신뢰성과 신용이 손상됩니다. 바이오마커 검사의 임상적 도입은 여전히 늦어져 의료 제공자가 이러한 진보된 진단법을 이용하는 의욕을 저하시키고 있습니다.

목차

제1장 암 바이오마커 시장 개요

제2장 주요 요약

제3장 시장에 관한 중요 인사이트

제4장 암 바이오마커 시장 전망

제5장 암 바이오마커 시장 전략

제6장 암 바이오마커 시장 규모

제7장 암 바이오마커 시장 규모 : 유형별

제8장 암 바이오마커 시장 : 제품별

제9장 암 바이오마커 시장 : 서비스별

제10장 암 바이오마커 시장 : 기술별

제11장 암 바이오마커 시장 : 용도별

제12장 암 바이오마커 시장 : 최종 사용자별

제13장 암 바이오마커 시장 : 설치 유형별

제14장 암 바이오마커 시장 : 기능별

제15장 암 바이오마커 시장 : 단계별

제16장 암 바이오마커 시장 : 지역별

제17장 경쟁 구도

제18장 기업 프로파일

KTH
영문 목차

영문목차

Cancer Biomarkers Market is anticipated to expand from $24.4 billion in 2024 to $60.3 billion by 2034, growing at a CAGR of approximately 9.5%. Cancer Biomarkers Market encompasses biological molecules that indicate the presence or progression of cancer, aiding in diagnosis, prognosis, and therapy selection. These biomarkers, found in blood, tissue, or other bodily fluids, facilitate personalized medicine by enabling targeted treatments. The market is expanding due to advancements in genomics, proteomics, and bioinformatics, alongside increasing cancer prevalence. Emphasis on early detection and precision medicine drives innovation, with a focus on developing non-invasive tests and integrating biomarker discovery with digital health technologies.

Industry Overview:

The Cancer Biomarkers Market is intricately influenced by global tariffs and geopolitical tensions, particularly in East Asia. Japan and South Korea are navigating trade barriers by bolstering domestic research and development, aiming to reduce dependency on foreign biotechnologies. China's strategic pivot towards self-sufficiency in medical research is accelerating, driven by export restrictions and a focus on indigenous innovation. Taiwan, while leading in biotech manufacturing, faces geopolitical vulnerabilities amidst US-China tensions. The global market for cancer biomarkers is robust, fueled by rising cancer prevalence and advancements in precision medicine. By 2035, the market is poised for significant growth, contingent on resilient supply chains and strategic alliances. Middle East conflicts potentially disrupt global supply chains, influencing energy prices and operational costs, thereby impacting market dynamics.

Market Segmentation
TypeGenomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Epigenetic Biomarkers
ProductAssay Kits, Reagents, Instruments, Software
ServicesSample Preparation, Biomarker Validation, Biomarker Testing, Data Analysis
TechnologyNext-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Chromatography
ApplicationDiagnostics, Drug Discovery and Development, Prognostics, Risk Assessment
End UserHospitals, Research Laboratories, Pharmaceutical Companies, Biotechnology Companies, Academic Institutes
Installation TypeOn-Premise, Cloud-Based
FunctionalityDetection, Monitoring, Profiling
StageEarly Detection, Prognosis, Therapeutic Response, Recurrence

Market Overview:

The Cancer Biomarkers Market is experiencing robust growth, primarily driven by advancements in personalized medicine and increasing prevalence of cancer. The protein biomarkers segment leads the market, attributed to their widespread use in cancer diagnosis, prognosis, and therapy monitoring. This segment's dominance is reinforced by its technological superiority in detecting specific cancer types and guiding targeted therapies. Genomic biomarkers are an emerging sub-segment, gaining traction due to advancements in next-generation sequencing and the growing emphasis on precision oncology. These biomarkers offer the potential to revolutionize cancer treatment by enabling early detection and personalized therapeutic strategies. The liquid biopsy sub-segment, encompassing circulating tumor DNA and exosome-based biomarkers, is poised to significantly impact the market due to its non-invasive nature and ability to provide real-time insights into tumor dynamics. As these emerging sub-segments continue to evolve, they promise to enhance diagnostic accuracy and treatment outcomes, driving further growth in the cancer biomarkers landscape.

Geographical Overview:

The cancer biomarkers market is witnessing substantial growth across diverse regions, each with unique dynamics. North America remains at the forefront, propelled by advanced healthcare infrastructure and heightened awareness of personalized medicine. Robust research and development activities further bolster the market's expansion in this region. Europe follows suit, with strong governmental support and investments in cancer research enhancing market growth. The region's emphasis on early diagnosis and prevention strategies significantly contributes to the demand for cancer biomarkers. Asia Pacific is experiencing rapid market expansion due to increasing cancer prevalence and improving healthcare infrastructure. Rising investments in biotechnology and personalized medicine drive the demand for cancer biomarkers. Latin America is an emerging market, with growing awareness of cancer diagnostics and increasing healthcare expenditure. Efforts to improve healthcare access and infrastructure are expected to boost the market further. The Middle East & Africa region is recognizing the potential of cancer biomarkers in improving patient outcomes. Investments in healthcare infrastructure and research initiatives are gradually enhancing market prospects in this region.

Competition Overview:

The cancer biomarkers market is predominantly led by diagnostics applications, with therapeutics and prognostics following closely. This hierarchy is largely influenced by the growing emphasis on early cancer detection and personalized medicine, which necessitate advanced diagnostic capabilities. Geographically, North America remains at the forefront of market leadership, bolstered by robust research infrastructure and high healthcare expenditure, whereas the Asia-Pacific region is witnessing accelerated growth due to increased healthcare investments and rising cancer prevalence. Key industry players are continuously enhancing their portfolios through strategic collaborations and innovations in biomarker discovery and validation. Regulatory frameworks, particularly in the United States and Europe, are pivotal in shaping market dynamics, as they establish stringent guidelines for biomarker validation and clinical use. The future trajectory of the cancer biomarkers market is promising, with advancements in genomics and proteomics paving the way for novel biomarker identification and utilization. While challenges such as regulatory hurdles and high development costs persist, the integration of artificial intelligence in biomarker analysis and the shift towards liquid biopsies present significant growth opportunities.

Recent Developments:

The Cancer Biomarkers Market has experienced notable developments recently. Roche has launched a new cancer biomarker test that promises to enhance early detection capabilities, marking a significant advancement in precision medicine. In M&A news, Thermo Fisher Scientific has acquired a leading biomarker company, aiming to expand its oncology diagnostics portfolio and strengthen its market position. Meanwhile, a strategic partnership was announced between AstraZeneca and Guardant Health to co-develop liquid biopsy tests, enhancing non-invasive cancer detection methods. The European Medicines Agency has updated its guidelines on biomarker validation, emphasizing the importance of robust clinical evidence, which could impact regulatory pathways for new biomarker tests. Lastly, a recent financial report from Bio-Rad Laboratories highlighted a substantial increase in their biomarker division's revenue, attributed to growing demand for personalized cancer therapies. These developments underscore the dynamic nature of the Cancer Biomarkers Market, driven by innovation and strategic collaborations.

Key Companies:

Biocept, Biodesix, Nant Health, Exact Sciences, Myriad Genetics, Guardant Health, Neo Genomics Laboratories, Caris Life Sciences, Foundation Medicine, Illumina, Thermo Fisher Scientific, QIAGEN, Perkin Elmer, Roche Diagnostics, Agilent Technologies, Hologic, Sysmex Corporation, Bio- Rad Laboratories, Quanterix, Adaptive Biotechnologies

Key Trends and Drivers:

The Cancer Biomarkers Market is experiencing robust growth driven by advancements in precision medicine and personalized healthcare. Key trends include the integration of artificial intelligence and machine learning in biomarker discovery, enhancing diagnostic accuracy and treatment efficacy. The increasing prevalence of cancer worldwide necessitates early detection and targeted therapies, propelling demand for innovative biomarker solutions. Drivers include government initiatives and funding supporting cancer research and biomarker development. The rise of liquid biopsy technologies offers non-invasive alternatives, improving patient compliance and monitoring. Additionally, collaborations between pharmaceutical companies and research institutions are accelerating biomarker research and commercialization. The growing emphasis on companion diagnostics is further bolstering market expansion. Opportunities abound in emerging markets where healthcare infrastructure is evolving, and access to advanced diagnostic tools is increasing. Companies that focus on developing cost-effective and accessible biomarker solutions stand to gain significant market share. The continuous evolution of genomic and proteomic technologies presents further avenues for growth, enabling more precise and comprehensive cancer management strategies. With ongoing innovations and strategic partnerships, the Cancer Biomarkers Market is poised for sustained advancement.

Restraints and Challenges:

The Cancer Biomarkers Market encounters several significant restraints and challenges. A primary challenge is the high cost of biomarker validation and development, which hampers widespread adoption and commercialization. The complexity and heterogeneity of cancer further complicate biomarker discovery, leading to prolonged research timelines and increased expenses. Regulatory hurdles present another obstacle, as stringent approval processes for new biomarkers delay market entry and increase costs. Additionally, the lack of standardized protocols and guidelines across laboratories leads to variability in test results, undermining reliability and trust. The limited availability of high-quality biological samples for research and validation constrains the pace of innovation. Furthermore, the integration of biomarker testing into clinical practice remains slow due to inadequate reimbursement frameworks, discouraging healthcare providers from utilizing these advanced diagnostics. These challenges collectively hinder the growth and accessibility of the cancer biomarkers market.

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Cancer Biomarkers Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Cancer Biomarkers Market Outlook

5: Cancer Biomarkers Market Strategy

6: Cancer Biomarkers Market Size

7: Cancer Biomarkers Market, by Type

8: Cancer Biomarkers Market, by Product

9: Cancer Biomarkers Market, by Services

10: Cancer Biomarkers Market, by Technology

11: Cancer Biomarkers Market, by Application

12: Cancer Biomarkers Market, by End User

13: Cancer Biomarkers Market, by Installation Type

14: Cancer Biomarkers Market, by Functionality

15: Cancer Biomarkers Market, by Stage

16: Cancer Biomarkers Market, by Region

17: Competitive Landscape

18: Company Profiles

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기